Treatment of testosterone deficiency syndrome in obese men with type 2 diabetes

Authors

DOI:

https://doi.org/10.18370/2309-4117.2022.63.19-22

Keywords:

diabetes mellitus, testosterone, aromatase inhibitor, men

Abstract

Objective: to study the effect of testosterone replacement therapy and aromatase inhibitors on the state of androgen supply in men with type 2 diabetes mellitus (DM-2) with obesity.
Materials and methods. We examined 38 men aged 37 to 62 years with DM-2 and obesity (main group) and 82 practically healthy men (control group). Blood concentration of luteinizing hormone (LH), total testosterone (Ttot), estradiol (E2) was determined by enzyme immunoassay. T concentration below 8.0 nmol/l was regarded as a sign of hypogonadism, the criterion for hyperestrogenemia was an increase of E2 level over 46 pg/ml. The criterion for obesity was a body mass index > 30 kg/m2.
Results. The average serum level of Ttot was significantly reduced compared to the control group. The average levels of E2 in patients of the main group did not differ from the control group. Determination of the average LH levels in the main group showed no probable difference compared to the same indicators in the control group. The Ttot/E2 ratio was lower in men with DM-2 and obesity, but this difference did not reach statistical significance. The Ttot/LH coefficient, which characterizes the effect of endogenous LH on the androgen-producing function of the testicles, was significantly decreased in the main group compared to the control group.
Testosterone replacement therapy significantly increased (p < 0.05) the mean blood levels of T. The average E2 levels increased in the dynamics of this therapy, but did not go beyond the normal range for adult men. Letrozole 1.25 mg 1 time per day every other day for 3 months had a positive effect. The E2 levels decreased from 30 to 60%, which was accompanied by an increase of the T concentration by 1.5–6.5 times compared with the baseline levels.
Conclusions. DM-2 and obesity are factors in the development of testosterone deficiency syndrome in men. A promising area for research is the use of aromatase inhibitors in men with DM-2, obesity, and testosterone deficiency syndrome caused by hyperestrogenemia.

Author Biographies

Y.V. Luchytskyi, SI “V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine”, Kyiv

MD, professor, head of the Department of Reproductive Endocrinology

H.A. Zubkova, SI “V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine”, Kyiv

PhD, chief researcher

V.M. Rybalchenko, SI “V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine”, Kyiv

Senior researcher

V.Y. Luchytskyi, SI “V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine”, Kyiv

MD, leading researcher

I.I. Skladanna, SI “V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine”, Kyiv

Research fellow

References

  1. Kapoor, D., Aldred, H., Clark, S., et al. “Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity.” Diabetes Care 30.4 (2007): 911–7. DOI: 10.2337/dc06-1426
  2. Ganz, M.L., Wintfeld, N., Li, Q., et al. “The association of body mass index with the risk of type 2 diabetes: a case-control study nested in an electronic health records system in the United States.” Diabetol Metab Syndr 6.1 (2014): 50. DOI: 10.1186/1758-5996-6-50
  3. Grossmann, M., Gianatti, E.J., Zajac, J.D. “Testosterone and type 2 diabetes.” Curr Opin Endocrinol Diabetes Obes 17.3 (2010): 247–56. DOI: 10.1097/MED.0b013e32833919cf
  4. Travison, T.G., Araujo, A.B., Kupelian, V., et al. “The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men.” J Clin Endocrinol Metab 92.2 (2007): 549–55. DOI: 10.1210/jc.2006-1859
  5. Haring, R., Ittermann, T., Völzke, H., et al. “Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania.” Aging Male 13.4 (2010): 247–57. DOI: 10.3109/13685538.2010.487553
  6. Ruige, J.B. “Does low testosterone affect adaptive properties of adipose tissue in obese men?” Arch Physiol Biochem 117.1 (2011): 18–22. DOI: 10.3109/13813455.2010.525239
  7. Larsen, S.H., Wagner, G., Heitmann, B.L. “Sexual function and obesity.” Int J Obes (Lond) 31.8 (2007): 1189–98. DOI: 10.1038/sj.ijo.0803604
  8. Lima, N., Cavaliere, H., Knobel, M., et al. “Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat.” Int J Obes Relat Metab Disord 24.11 (2000): 1433–7. DOI: 10.1038/sj.ijo.0801406
  9. Vermeulen, A., Kaufman, J.M., Deslypere, J.P., Thomas, G. “Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men.” J Clin Endocrinol Metab 76.5 (1993): 1140–6. DOI: 10.1210/jcem.76.5.8496304
  10. Kapoor, D., Aldred, H., Clark, S., et al. “Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity.” Diabetes Care 30 (2007): 911–7.
  11. Grossmann, M., Thomas, M.C., Panagiotopoulos, S., et al. “Low testosterone levels are common and associated with insulin resistance in men with diabetes.” J Clin Endocrinol Metab 93.5 (2008): 1834–40. DOI: 10.1210/jc.2007-2177
  12. Vermeulen, A., Kaufman, J.M., Goemaere, S., van Pottelberg, I. “Estradiol in elderly men.” Aging Male 5.2 (2002): 98–102.
  13. Dhindsa, S., Furlanetto, R., Vora, M., et al. “Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes.” Diabetes Care 34.8 (2011): 1854–9. DOI: 10.2337/dc11-0208
  14. Tajar, A., Forti, G., O’Neill, T.W., et al. “Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study.” J Clin Endocrinol Metab 95.4 (2010): 1810–8. DOI: 10.1210/jc.2009-1796
  15. Baccetti, B., La Marca, A., Piomboni, P., et al. “Insulin-dependent diabetes in men is associated with hypothalamo-pituitary derangement and with impairment in semen quality.” Hum Reprod 17.10 (2002): 2673–7. DOI: 10.1093/humrep/17.10.2673
  16. Corona, G., Monami, M., Rastrelli, G., et al. “Testosterone and metabolic syndrome: a meta-analysis study.” J Sex Med 8.1 (2011): 272–83. DOI: 10.1111/j.1743-6109.2010.01991.x
  17. Huhtaniemi, I. “Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment.” Asian J Androl 16.2 (2014): 192–202. DOI: 10.4103/1008-682X.122336
  18. Kapoor, D., Goodwin, E., Channer, K.S., Jones, T.H. “Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.” Eur J Endocrinol 154.6 (2006): 899–906. DOI: 10.1530/eje.1.02166
  19. Channer, K., Dumas, C. “Prospective evaluation of the effects of testosterone therapy in hypogonadal men with type 2 diabetes or metabolic syndrome: demographic analysis of TIMES2 study.” Diabetes Vasc Dis Res 4 (2007): 164.
  20. Bhattacharya, R.K., Khera, M., Blick, G., et al. “Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS).” BMC Endocr Disord 11 (2011): 18. DOI: 10.1186/1472-6823-11-18
  21. Svartberg, J., Agledahl, I., Figenschau, Y., et al. “Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip.” Int J Impot Res 20.4 (2008): 378–87. DOI: 10.1038/ijir.2008.19
  22. Saad, F., Aversa, A., Isidori, A.M., Gooren, L.J. “Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review.” Curr Diabetes Rev 8.2 (2012): 131–43. DOI: 10.2174/157339912799424573
  23. Wu, F.C., Tajar, A., Beynon, J.M., et al. “Identification of late-onset hypogonadism in middle-aged and elderly men.” N Engl J Med 363.2 (2010): 123–35. DOI: 10.1056/NEJMoa0911101
  24. Corona, G., Giorda, C.B., Cucinotta, D., et al. “Sexual dysfunction at the onset of type 2 diabetes: the interplay of depression, hormonal and cardiovascular factors.” J Sex Med 11.8 (2014): 2065–73. DOI: 10.1111/jsm.12601
  25. Selvin, E., Feinleib, M., Zhang, L., et al. “Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III).” Diabetes Care 30.2 (2007): 234–8. DOI: 10.2337/dc06-1579
  26. Zohdy, W., Kamal, E.E., Ibrahim, Y. “Androgen deficiency and abnormal penile duplex parameters in obese men with erectile dysfunction.” J Sex Med 4.3 (2007): 797–808. DOI: 10.1111/j.1743-6109.2007.00499.x

Downloads

Published

2022-05-27

How to Cite

Luchytskyi, Y., Zubkova, H., Rybalchenko, V., Luchytskyi, V., & Skladanna, I. (2022). Treatment of testosterone deficiency syndrome in obese men with type 2 diabetes. REPRODUCTIVE ENDOCRINOLOGY, (63-64), 19–22. https://doi.org/10.18370/2309-4117.2022.63.19-22

Issue

No. 63-64 (2022)

Section

Endocrinology

License

Copyright (c) 2022 Є.В. Лучицький, Г.А. Зубкова, В.М. Рибальченко, В.Є. Лучицький, І.І. Складанна

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.